Amneal Pharmaceuticals, Inc. (AMRX): Price and Financial Metrics
AMRX Price/Volume Stats
| Current price | $8.62 | 52-week high | $8.72 |
| Prev. close | $8.47 | 52-week low | $3.36 |
| Day low | $8.50 | Volume | 625,900 |
| Day high | $8.64 | Avg. volume | 1,485,903 |
| 50-day MA | $7.74 | Dividend yield | N/A |
| 200-day MA | $6.34 | Market Cap | 2.66B |
AMRX Stock Price Chart Interactive Chart >
Amneal Pharmaceuticals, Inc. (AMRX) Company Bio
Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.
Latest AMRX News From Around the Web
Below are the latest news stories about AMNEAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMRX as an investment opportunity.
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceBRIDGEWATER, N.J., December 21, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Chirag will present on January 10th at 11:15 AM PST, and a live webcast will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available for 30 days f |
Amneal Announces Move to NasdaqBRIDGEWATER, N.J., December 15, 2023--Amneal Pharmaceuticals, Inc. ("Amneal") (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol "AMRX". Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index. |
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)BRIDGEWATER, N.J. & PORTO, Portugal, December 07, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") and BIAL - Portela & Ca., S.A. ("BIAL"), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023. Amneal expects to begin distribution of ONGENTYS® in early 2024. |
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel CapsulesBRIDGEWATER, N.J., December 01, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") and Strides Pharma Science Limited ("Strides") today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023. |
Should You Be Excited About Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) 20% Return On Equity?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
AMRX Price Returns
| 1-mo | 7.21% |
| 3-mo | 28.27% |
| 6-mo | 41.78% |
| 1-year | 109.73% |
| 3-year | 70.69% |
| 5-year | 164.42% |
| YTD | 42.01% |
| 2023 | 205.03% |
| 2022 | -58.46% |
| 2021 | 4.81% |
| 2020 | -5.19% |
| 2019 | -64.38% |
Continue Researching AMRX
Here are a few links from around the web to help you further your research on Amneal Pharmaceuticals Inc's stock as an investment opportunity:Amneal Pharmaceuticals Inc (AMRX) Stock Price | Nasdaq
Amneal Pharmaceuticals Inc (AMRX) Stock Quote, History and News - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...